nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Progesterone—uterine cancer	0.324	0.48	CbGbCtD
Bosentan—ABCB11—Doxorubicin—uterine cancer	0.099	0.146	CbGbCtD
Bosentan—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0865	0.128	CbGbCtD
Bosentan—CYP2C9—Progesterone—uterine cancer	0.0573	0.0848	CbGbCtD
Bosentan—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0503	0.0744	CbGbCtD
Bosentan—CYP3A4—Progesterone—uterine cancer	0.0333	0.0493	CbGbCtD
Bosentan—CYP3A4—Etoposide—uterine cancer	0.0149	0.0221	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—uterine cancer	0.0102	0.015	CbGbCtD
Bosentan—EDNRB—myometrium—uterine cancer	0.00556	0.0885	CbGeAlD
Bosentan—EDNRA—myometrium—uterine cancer	0.0046	0.0731	CbGeAlD
Bosentan—EDNRB—uterine cervix—uterine cancer	0.00433	0.0688	CbGeAlD
Bosentan—EDNRB—decidua—uterine cancer	0.00412	0.0656	CbGeAlD
Bosentan—EDNRB—endometrium—uterine cancer	0.00391	0.0623	CbGeAlD
Bosentan—EDNRB—mammalian vulva—uterine cancer	0.00379	0.0602	CbGeAlD
Bosentan—EDNRB—uterus—uterine cancer	0.00361	0.0574	CbGeAlD
Bosentan—EDNRA—uterine cervix—uterine cancer	0.00358	0.0569	CbGeAlD
Bosentan—EDNRA—decidua—uterine cancer	0.00341	0.0542	CbGeAlD
Bosentan—EDNRA—endometrium—uterine cancer	0.00323	0.0515	CbGeAlD
Bosentan—EDNRA—mammalian vulva—uterine cancer	0.00313	0.0498	CbGeAlD
Bosentan—EDNRA—uterus—uterine cancer	0.00298	0.0474	CbGeAlD
Bosentan—EDNRB—female gonad—uterine cancer	0.00295	0.0469	CbGeAlD
Bosentan—EDNRB—vagina—uterine cancer	0.00293	0.0466	CbGeAlD
Bosentan—EDNRA—female gonad—uterine cancer	0.00244	0.0388	CbGeAlD
Bosentan—EDNRA—vagina—uterine cancer	0.00242	0.0386	CbGeAlD
Bosentan—EDNRB—lymph node—uterine cancer	0.0019	0.0302	CbGeAlD
Bosentan—EDNRA—lymph node—uterine cancer	0.00157	0.0249	CbGeAlD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00134	0.0889	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.000959	0.0636	CbGpPWpGaD
Bosentan—ABCB11—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—AKR1C1—uterine cancer	0.000906	0.0601	CbGpPWpGaD
Bosentan—CYP2C9—female reproductive system—uterine cancer	0.000887	0.0141	CbGeAlD
Bosentan—CYP3A4—renal system—uterine cancer	0.000844	0.0134	CbGeAlD
Bosentan—ABCB11—Synthesis of bile acids and bile salts—AKR1C1—uterine cancer	0.000825	0.0547	CbGpPWpGaD
Bosentan—ABCB11—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—AKR1C3—uterine cancer	0.000698	0.0463	CbGpPWpGaD
Bosentan—CYP3A4—female reproductive system—uterine cancer	0.000676	0.0108	CbGeAlD
Bosentan—ABCB11—Bile acid and bile salt metabolism—AKR1C1—uterine cancer	0.000655	0.0434	CbGpPWpGaD
Bosentan—ABCB11—Synthesis of bile acids and bile salts—AKR1C3—uterine cancer	0.000635	0.0421	CbGpPWpGaD
Bosentan—ABCB11—Bile acid and bile salt metabolism—AKR1C3—uterine cancer	0.000504	0.0334	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—uterine cancer	0.000504	0.0334	CbGpPWpGaD
Bosentan—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000437	0.029	CbGpPWpGaD
Bosentan—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000337	0.0223	CbGpPWpGaD
Bosentan—Orthostatic hypotension—Epirubicin—uterine cancer	0.00022	0.000892	CcSEcCtD
Bosentan—Abdominal pain upper—Epirubicin—uterine cancer	0.00022	0.000892	CcSEcCtD
Bosentan—Affect lability—Doxorubicin—uterine cancer	0.000219	0.000889	CcSEcCtD
Bosentan—Hypokalaemia—Epirubicin—uterine cancer	0.000219	0.000889	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000219	0.000887	CcSEcCtD
Bosentan—Discomfort—Etoposide—uterine cancer	0.000217	0.000883	CcSEcCtD
Bosentan—Nasopharyngitis—Epirubicin—uterine cancer	0.000215	0.000873	CcSEcCtD
Bosentan—Hypersensitivity—Dactinomycin—uterine cancer	0.000215	0.000872	CcSEcCtD
Bosentan—Cardiac arrest—Doxorubicin—uterine cancer	0.000212	0.000859	CcSEcCtD
Bosentan—Anaphylactic shock—Etoposide—uterine cancer	0.000211	0.000856	CcSEcCtD
Bosentan—Mood swings—Doxorubicin—uterine cancer	0.000211	0.000856	CcSEcCtD
Bosentan—Infection—Etoposide—uterine cancer	0.00021	0.000851	CcSEcCtD
Bosentan—Abdominal distension—Epirubicin—uterine cancer	0.000209	0.00085	CcSEcCtD
Bosentan—Asthenia—Dactinomycin—uterine cancer	0.000209	0.000849	CcSEcCtD
Bosentan—Influenza—Epirubicin—uterine cancer	0.000208	0.000844	CcSEcCtD
Bosentan—Asthma—Epirubicin—uterine cancer	0.000208	0.000844	CcSEcCtD
Bosentan—Dehydration—Doxorubicin—uterine cancer	0.000207	0.00084	CcSEcCtD
Bosentan—Thrombocytopenia—Etoposide—uterine cancer	0.000207	0.000838	CcSEcCtD
Bosentan—Tachycardia—Etoposide—uterine cancer	0.000206	0.000836	CcSEcCtD
Bosentan—Eosinophilia—Epirubicin—uterine cancer	0.000206	0.000836	CcSEcCtD
Bosentan—Liver function test abnormal—Doxorubicin—uterine cancer	0.000206	0.000834	CcSEcCtD
Bosentan—Skin disorder—Etoposide—uterine cancer	0.000205	0.000832	CcSEcCtD
Bosentan—Dry skin—Doxorubicin—uterine cancer	0.000204	0.000828	CcSEcCtD
Bosentan—Hyperhidrosis—Etoposide—uterine cancer	0.000204	0.000828	CcSEcCtD
Bosentan—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000203	0.000825	CcSEcCtD
Bosentan—Abdominal pain upper—Doxorubicin—uterine cancer	0.000203	0.000825	CcSEcCtD
Bosentan—Hypokalaemia—Doxorubicin—uterine cancer	0.000203	0.000822	CcSEcCtD
Bosentan—Angina pectoris—Epirubicin—uterine cancer	0.000203	0.000822	CcSEcCtD
Bosentan—Anorexia—Etoposide—uterine cancer	0.000201	0.000816	CcSEcCtD
Bosentan—Bronchitis—Epirubicin—uterine cancer	0.0002	0.000812	CcSEcCtD
Bosentan—Diarrhoea—Dactinomycin—uterine cancer	0.000199	0.00081	CcSEcCtD
Bosentan—Nasopharyngitis—Doxorubicin—uterine cancer	0.000199	0.000808	CcSEcCtD
Bosentan—Hypotension—Etoposide—uterine cancer	0.000197	0.0008	CcSEcCtD
Bosentan—Neutropenia—Epirubicin—uterine cancer	0.000194	0.000789	CcSEcCtD
Bosentan—Dysuria—Epirubicin—uterine cancer	0.000194	0.000789	CcSEcCtD
Bosentan—Abdominal distension—Doxorubicin—uterine cancer	0.000194	0.000786	CcSEcCtD
Bosentan—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000193	0.000784	CcSEcCtD
Bosentan—Asthma—Doxorubicin—uterine cancer	0.000192	0.000781	CcSEcCtD
Bosentan—Influenza—Doxorubicin—uterine cancer	0.000192	0.000781	CcSEcCtD
Bosentan—Pollakiuria—Epirubicin—uterine cancer	0.000192	0.00078	CcSEcCtD
Bosentan—Eosinophilia—Doxorubicin—uterine cancer	0.000191	0.000773	CcSEcCtD
Bosentan—Paraesthesia—Etoposide—uterine cancer	0.000189	0.000769	CcSEcCtD
Bosentan—Weight increased—Epirubicin—uterine cancer	0.000189	0.000768	CcSEcCtD
Bosentan—Weight decreased—Epirubicin—uterine cancer	0.000188	0.000764	CcSEcCtD
Bosentan—Dyspnoea—Etoposide—uterine cancer	0.000188	0.000763	CcSEcCtD
Bosentan—Hyperglycaemia—Epirubicin—uterine cancer	0.000188	0.000761	CcSEcCtD
Bosentan—Somnolence—Etoposide—uterine cancer	0.000188	0.000761	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—uterine cancer	0.000187	0.000761	CcSEcCtD
Bosentan—Pneumonia—Epirubicin—uterine cancer	0.000186	0.000757	CcSEcCtD
Bosentan—Infestation NOS—Epirubicin—uterine cancer	0.000185	0.000753	CcSEcCtD
Bosentan—Infestation—Epirubicin—uterine cancer	0.000185	0.000753	CcSEcCtD
Bosentan—Vomiting—Dactinomycin—uterine cancer	0.000185	0.000752	CcSEcCtD
Bosentan—Bronchitis—Doxorubicin—uterine cancer	0.000185	0.000751	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000184	0.000746	CcSEcCtD
Bosentan—Rash—Dactinomycin—uterine cancer	0.000184	0.000746	CcSEcCtD
Bosentan—Decreased appetite—Etoposide—uterine cancer	0.000183	0.000744	CcSEcCtD
Bosentan—Renal failure—Epirubicin—uterine cancer	0.000182	0.00074	CcSEcCtD
Bosentan—Gastrointestinal disorder—Etoposide—uterine cancer	0.000182	0.000739	CcSEcCtD
Bosentan—Fatigue—Etoposide—uterine cancer	0.000182	0.000738	CcSEcCtD
Bosentan—Jaundice—Epirubicin—uterine cancer	0.000181	0.000734	CcSEcCtD
Bosentan—Stomatitis—Epirubicin—uterine cancer	0.000181	0.000734	CcSEcCtD
Bosentan—Constipation—Etoposide—uterine cancer	0.00018	0.000732	CcSEcCtD
Bosentan—Pain—Etoposide—uterine cancer	0.00018	0.000732	CcSEcCtD
Bosentan—Urinary tract infection—Epirubicin—uterine cancer	0.00018	0.000732	CcSEcCtD
Bosentan—Conjunctivitis—Epirubicin—uterine cancer	0.00018	0.000732	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—uterine cancer	0.00018	0.00073	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—uterine cancer	0.00018	0.00073	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000179	0.000726	CcSEcCtD
Bosentan—Pollakiuria—Doxorubicin—uterine cancer	0.000178	0.000721	CcSEcCtD
Bosentan—Haematuria—Epirubicin—uterine cancer	0.000177	0.000718	CcSEcCtD
Bosentan—Hepatobiliary disease—Epirubicin—uterine cancer	0.000175	0.000712	CcSEcCtD
Bosentan—Weight increased—Doxorubicin—uterine cancer	0.000175	0.000711	CcSEcCtD
Bosentan—Epistaxis—Epirubicin—uterine cancer	0.000175	0.00071	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—uterine cancer	0.000174	0.000707	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—uterine cancer	0.000174	0.000706	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—uterine cancer	0.000174	0.000705	CcSEcCtD
Bosentan—Nausea—Dactinomycin—uterine cancer	0.000173	0.000703	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—uterine cancer	0.000173	0.0007	CcSEcCtD
Bosentan—Gastrointestinal pain—Etoposide—uterine cancer	0.000173	0.0007	CcSEcCtD
Bosentan—Infestation—Doxorubicin—uterine cancer	0.000172	0.000696	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—uterine cancer	0.000172	0.000696	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00017	0.00069	CcSEcCtD
Bosentan—Bradycardia—Epirubicin—uterine cancer	0.000169	0.000688	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—uterine cancer	0.000169	0.000685	CcSEcCtD
Bosentan—Urticaria—Etoposide—uterine cancer	0.000168	0.00068	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—uterine cancer	0.000167	0.000679	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—uterine cancer	0.000167	0.000679	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—uterine cancer	0.000167	0.000679	CcSEcCtD
Bosentan—Abdominal pain—Etoposide—uterine cancer	0.000167	0.000677	CcSEcCtD
Bosentan—Body temperature increased—Etoposide—uterine cancer	0.000167	0.000677	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—uterine cancer	0.000167	0.000677	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—uterine cancer	0.000167	0.000677	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—uterine cancer	0.000166	0.000676	CcSEcCtD
Bosentan—Haemorrhage—Epirubicin—uterine cancer	0.000166	0.000676	CcSEcCtD
Bosentan—Hypoaesthesia—Epirubicin—uterine cancer	0.000166	0.000672	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—uterine cancer	0.000164	0.000667	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—uterine cancer	0.000164	0.000666	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—uterine cancer	0.000164	0.000664	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—uterine cancer	0.000163	0.000662	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000162	0.000659	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—uterine cancer	0.000162	0.000657	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—uterine cancer	0.000161	0.000653	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—uterine cancer	0.000157	0.000639	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—uterine cancer	0.000157	0.000636	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—uterine cancer	0.000156	0.000631	CcSEcCtD
Bosentan—Hypersensitivity—Etoposide—uterine cancer	0.000155	0.000631	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—uterine cancer	0.000155	0.00063	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—uterine cancer	0.000155	0.000628	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—uterine cancer	0.000154	0.000627	CcSEcCtD
Bosentan—Flushing—Epirubicin—uterine cancer	0.000154	0.000627	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—uterine cancer	0.000154	0.000625	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—uterine cancer	0.000154	0.000625	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—uterine cancer	0.000153	0.000622	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—uterine cancer	0.000152	0.000617	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—uterine cancer	0.000152	0.000616	CcSEcCtD
Bosentan—Asthenia—Etoposide—uterine cancer	0.000151	0.000614	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—uterine cancer	0.000151	0.000613	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—uterine cancer	0.000151	0.000613	CcSEcCtD
Bosentan—Immune system disorder—Epirubicin—uterine cancer	0.00015	0.00061	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—uterine cancer	0.00015	0.000609	CcSEcCtD
Bosentan—Chills—Epirubicin—uterine cancer	0.000149	0.000606	CcSEcCtD
Bosentan—Pruritus—Etoposide—uterine cancer	0.000149	0.000606	CcSEcCtD
Bosentan—EDNRB—Endothelins—HRAS—uterine cancer	0.000149	0.00985	CbGpPWpGaD
Bosentan—Mental disorder—Epirubicin—uterine cancer	0.000146	0.000592	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—uterine cancer	0.000146	0.000591	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—uterine cancer	0.000145	0.000588	CcSEcCtD
Bosentan—Erythema—Epirubicin—uterine cancer	0.000145	0.000588	CcSEcCtD
Bosentan—Diarrhoea—Etoposide—uterine cancer	0.000144	0.000586	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—uterine cancer	0.000144	0.000584	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—uterine cancer	0.000144	0.000583	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—uterine cancer	0.000143	0.00058	CcSEcCtD
Bosentan—Flushing—Doxorubicin—uterine cancer	0.000143	0.00058	CcSEcCtD
Bosentan—Flatulence—Epirubicin—uterine cancer	0.000143	0.00058	CcSEcCtD
Bosentan—Back pain—Epirubicin—uterine cancer	0.00014	0.000569	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—uterine cancer	0.00014	0.000567	CcSEcCtD
Bosentan—Dizziness—Etoposide—uterine cancer	0.00014	0.000566	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—uterine cancer	0.000139	0.000565	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—uterine cancer	0.000139	0.000565	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—uterine cancer	0.000139	0.000563	CcSEcCtD
Bosentan—Chills—Doxorubicin—uterine cancer	0.000138	0.000561	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—uterine cancer	0.000137	0.000554	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000136	0.009	CbGpPWpGaD
Bosentan—Mental disorder—Doxorubicin—uterine cancer	0.000135	0.000548	CcSEcCtD
Bosentan—Vomiting—Etoposide—uterine cancer	0.000134	0.000544	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—uterine cancer	0.000134	0.000544	CcSEcCtD
Bosentan—Erythema—Doxorubicin—uterine cancer	0.000134	0.000544	CcSEcCtD
Bosentan—Anaemia—Epirubicin—uterine cancer	0.000134	0.000544	CcSEcCtD
Bosentan—Rash—Etoposide—uterine cancer	0.000133	0.00054	CcSEcCtD
Bosentan—Dermatitis—Etoposide—uterine cancer	0.000133	0.000539	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000132	0.00878	CbGpPWpGaD
Bosentan—Headache—Etoposide—uterine cancer	0.000132	0.000536	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—uterine cancer	0.000132	0.000536	CcSEcCtD
Bosentan—EDNRB—Endothelins—AKT1—uterine cancer	0.000131	0.0087	CbGpPWpGaD
Bosentan—Vertigo—Epirubicin—uterine cancer	0.00013	0.000528	CcSEcCtD
Bosentan—Syncope—Epirubicin—uterine cancer	0.00013	0.000527	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—uterine cancer	0.00013	0.000526	CcSEcCtD
Bosentan—Back pain—Doxorubicin—uterine cancer	0.00013	0.000526	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000129	0.00859	CbGpPWpGaD
Bosentan—Muscle spasms—Doxorubicin—uterine cancer	0.000129	0.000523	CcSEcCtD
Bosentan—Palpitations—Epirubicin—uterine cancer	0.000128	0.00052	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—uterine cancer	0.000127	0.000517	CcSEcCtD
Bosentan—Cough—Epirubicin—uterine cancer	0.000126	0.000513	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—uterine cancer	0.000126	0.000513	CcSEcCtD
Bosentan—Nausea—Etoposide—uterine cancer	0.000125	0.000509	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—uterine cancer	0.000124	0.000503	CcSEcCtD
Bosentan—Chest pain—Epirubicin—uterine cancer	0.000123	0.000501	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—uterine cancer	0.000123	0.000501	CcSEcCtD
Bosentan—Anxiety—Epirubicin—uterine cancer	0.000123	0.000499	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000123	0.000497	CcSEcCtD
Bosentan—Discomfort—Epirubicin—uterine cancer	0.000122	0.000495	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—uterine cancer	0.000121	0.00049	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—uterine cancer	0.00012	0.000489	CcSEcCtD
Bosentan—Syncope—Doxorubicin—uterine cancer	0.00012	0.000488	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—uterine cancer	0.00012	0.000487	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000118	0.00786	CbGpPWpGaD
Bosentan—Palpitations—Doxorubicin—uterine cancer	0.000118	0.000481	CcSEcCtD
Bosentan—Oedema—Epirubicin—uterine cancer	0.000118	0.00048	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—uterine cancer	0.000118	0.00048	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—uterine cancer	0.000118	0.000478	CcSEcCtD
Bosentan—Infection—Epirubicin—uterine cancer	0.000117	0.000477	CcSEcCtD
Bosentan—Cough—Doxorubicin—uterine cancer	0.000117	0.000475	CcSEcCtD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000117	0.00775	CbGpPWpGaD
Bosentan—Shock—Epirubicin—uterine cancer	0.000116	0.000472	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—uterine cancer	0.000116	0.000471	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—uterine cancer	0.000116	0.00047	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—uterine cancer	0.000115	0.000468	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—uterine cancer	0.000115	0.000466	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—uterine cancer	0.000114	0.000464	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—uterine cancer	0.000114	0.000463	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—uterine cancer	0.000114	0.000463	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—uterine cancer	0.000114	0.000462	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000113	0.00046	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—uterine cancer	0.000113	0.000458	CcSEcCtD
Bosentan—Anorexia—Epirubicin—uterine cancer	0.000113	0.000458	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—uterine cancer	0.000112	0.000453	CcSEcCtD
Bosentan—Hypotension—Epirubicin—uterine cancer	0.000111	0.000449	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—uterine cancer	0.000109	0.000444	CcSEcCtD
Bosentan—Oedema—Doxorubicin—uterine cancer	0.000109	0.000444	CcSEcCtD
Bosentan—Infection—Doxorubicin—uterine cancer	0.000109	0.000441	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000108	0.000437	CcSEcCtD
Bosentan—Shock—Doxorubicin—uterine cancer	0.000108	0.000437	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—uterine cancer	0.000107	0.000436	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—uterine cancer	0.000107	0.000435	CcSEcCtD
Bosentan—Insomnia—Epirubicin—uterine cancer	0.000107	0.000434	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—uterine cancer	0.000107	0.000433	CcSEcCtD
Bosentan—EDNRA—Endothelins—HRAS—uterine cancer	0.000106	0.00705	CbGpPWpGaD
Bosentan—Skin disorder—Doxorubicin—uterine cancer	0.000106	0.000431	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—uterine cancer	0.000106	0.000431	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—uterine cancer	0.000106	0.000429	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—uterine cancer	0.000105	0.000428	CcSEcCtD
Bosentan—Somnolence—Epirubicin—uterine cancer	0.000105	0.000427	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000105	0.00694	CbGpPWpGaD
Bosentan—Anorexia—Doxorubicin—uterine cancer	0.000104	0.000423	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—uterine cancer	0.000104	0.000423	CcSEcCtD
Bosentan—Decreased appetite—Epirubicin—uterine cancer	0.000103	0.000417	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—uterine cancer	0.000102	0.000415	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000102	0.000414	CcSEcCtD
Bosentan—Fatigue—Epirubicin—uterine cancer	0.000102	0.000414	CcSEcCtD
Bosentan—Pain—Epirubicin—uterine cancer	0.000101	0.00041	CcSEcCtD
Bosentan—Constipation—Epirubicin—uterine cancer	0.000101	0.00041	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—uterine cancer	9.97e-05	0.000405	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—uterine cancer	9.9e-05	0.000402	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—uterine cancer	9.83e-05	0.000399	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—STAR—uterine cancer	9.81e-05	0.0065	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	9.81e-05	0.0065	CbGpPWpGaD
Bosentan—Dyspnoea—Doxorubicin—uterine cancer	9.76e-05	0.000396	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—uterine cancer	9.73e-05	0.000395	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—uterine cancer	9.67e-05	0.000393	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—uterine cancer	9.63e-05	0.000391	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	9.61e-05	0.00637	CbGpPWpGaD
Bosentan—Decreased appetite—Doxorubicin—uterine cancer	9.51e-05	0.000386	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—CCL2—uterine cancer	9.48e-05	0.00628	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Doxorubicin—uterine cancer	9.45e-05	0.000383	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—uterine cancer	9.43e-05	0.000383	CcSEcCtD
Bosentan—Urticaria—Epirubicin—uterine cancer	9.39e-05	0.000381	CcSEcCtD
Bosentan—EDNRA—Endothelins—AKT1—uterine cancer	9.39e-05	0.00623	CbGpPWpGaD
Bosentan—Pain—Doxorubicin—uterine cancer	9.36e-05	0.00038	CcSEcCtD
Bosentan—Constipation—Doxorubicin—uterine cancer	9.36e-05	0.00038	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—uterine cancer	9.35e-05	0.000379	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—uterine cancer	9.35e-05	0.000379	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	9.05e-05	0.006	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—uterine cancer	8.95e-05	0.000363	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	8.88e-05	0.00589	CbGpPWpGaD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	8.72e-05	0.00578	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—uterine cancer	8.71e-05	0.000354	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—uterine cancer	8.69e-05	0.000353	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—uterine cancer	8.65e-05	0.000351	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—uterine cancer	8.65e-05	0.000351	CcSEcCtD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	8.6e-05	0.00571	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKR1B10—uterine cancer	8.52e-05	0.00565	CbGpPWpGaD
Bosentan—Asthenia—Epirubicin—uterine cancer	8.48e-05	0.000344	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	8.41e-05	0.00558	CbGpPWpGaD
Bosentan—Pruritus—Epirubicin—uterine cancer	8.37e-05	0.00034	CcSEcCtD
Bosentan—Diarrhoea—Epirubicin—uterine cancer	8.09e-05	0.000328	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—uterine cancer	8.06e-05	0.000327	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—uterine cancer	7.85e-05	0.000319	CcSEcCtD
Bosentan—Dizziness—Epirubicin—uterine cancer	7.82e-05	0.000317	CcSEcCtD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	7.81e-05	0.00518	CbGpPWpGaD
Bosentan—Pruritus—Doxorubicin—uterine cancer	7.74e-05	0.000314	CcSEcCtD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	7.71e-05	0.00511	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	7.61e-05	0.00504	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—uterine cancer	7.52e-05	0.000305	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—CXCL8—uterine cancer	7.49e-05	0.00497	CbGpPWpGaD
Bosentan—Diarrhoea—Doxorubicin—uterine cancer	7.49e-05	0.000304	CcSEcCtD
Bosentan—Rash—Epirubicin—uterine cancer	7.46e-05	0.000303	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—uterine cancer	7.45e-05	0.000302	CcSEcCtD
Bosentan—Headache—Epirubicin—uterine cancer	7.41e-05	0.000301	CcSEcCtD
Bosentan—Dizziness—Doxorubicin—uterine cancer	7.24e-05	0.000294	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	7.2e-05	0.00477	CbGpPWpGaD
Bosentan—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	7.11e-05	0.00472	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.07e-05	0.00469	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RNF43—uterine cancer	7.06e-05	0.00468	CbGpPWpGaD
Bosentan—Nausea—Epirubicin—uterine cancer	7.02e-05	0.000285	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	7.02e-05	0.00466	CbGpPWpGaD
Bosentan—Vomiting—Doxorubicin—uterine cancer	6.96e-05	0.000282	CcSEcCtD
Bosentan—Rash—Doxorubicin—uterine cancer	6.9e-05	0.00028	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—uterine cancer	6.89e-05	0.00028	CcSEcCtD
Bosentan—Headache—Doxorubicin—uterine cancer	6.85e-05	0.000278	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—CCL2—uterine cancer	6.76e-05	0.00448	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—PIK3CA—uterine cancer	6.73e-05	0.00446	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	6.55e-05	0.00434	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—uterine cancer	6.5e-05	0.000264	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—INHBA—uterine cancer	6.46e-05	0.00428	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	6.36e-05	0.00421	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.34e-05	0.0042	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	6.17e-05	0.00409	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKR1B10—uterine cancer	6.1e-05	0.00404	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SRD5A2—uterine cancer	6.04e-05	0.00401	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NDUFB11—uterine cancer	6.04e-05	0.00401	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	6.02e-05	0.00399	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	5.97e-05	0.00396	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	5.87e-05	0.00389	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKR1C1—uterine cancer	5.81e-05	0.00385	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	5.75e-05	0.00381	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	5.67e-05	0.00376	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	5.57e-05	0.00369	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.55e-05	0.00368	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	5.54e-05	0.00368	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	5.44e-05	0.00361	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	5.42e-05	0.00359	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CXCL8—uterine cancer	5.35e-05	0.00355	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	5.1e-05	0.00338	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RNF43—uterine cancer	5.05e-05	0.00335	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	5.03e-05	0.00334	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	5.03e-05	0.00333	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CCL2—uterine cancer	4.84e-05	0.00321	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—PIK3CA—uterine cancer	4.81e-05	0.00319	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	4.75e-05	0.00315	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	4.69e-05	0.00311	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.66e-05	0.00309	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—INHBA—uterine cancer	4.62e-05	0.00306	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	4.53e-05	0.003	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKR1C3—uterine cancer	4.48e-05	0.00297	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKR1B1—uterine cancer	4.37e-05	0.0029	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—STAR—uterine cancer	4.37e-05	0.0029	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PGR—uterine cancer	4.36e-05	0.00289	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.32e-05	0.00286	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	4.3e-05	0.00285	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—YWHAE—uterine cancer	4.16e-05	0.00276	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKR1C1—uterine cancer	4.16e-05	0.00276	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	4.07e-05	0.0027	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—FBXW7—uterine cancer	3.99e-05	0.00265	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	3.98e-05	0.00264	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL8—uterine cancer	3.83e-05	0.00254	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	3.75e-05	0.00249	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	3.7e-05	0.00246	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.57e-05	0.00237	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STK11—uterine cancer	3.49e-05	0.00231	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CCL2—uterine cancer	3.47e-05	0.0023	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—POLD1—uterine cancer	3.43e-05	0.00227	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.37e-05	0.00223	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.32e-05	0.0022	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.27e-05	0.00217	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.27e-05	0.00217	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SOCS3—uterine cancer	3.26e-05	0.00216	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKR1C1—uterine cancer	3.21e-05	0.00213	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKR1C3—uterine cancer	3.2e-05	0.00212	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.13e-05	0.00208	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN2B—uterine cancer	3.13e-05	0.00207	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PGR—uterine cancer	3.12e-05	0.00207	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IGF1R—uterine cancer	3.04e-05	0.00201	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCL8—uterine cancer	3.02e-05	0.002	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—YWHAE—uterine cancer	2.98e-05	0.00197	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—RRM2—uterine cancer	2.86e-05	0.0019	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FBXW7—uterine cancer	2.85e-05	0.00189	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SMAD3—uterine cancer	2.85e-05	0.00189	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—DCN—uterine cancer	2.77e-05	0.00184	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCL8—uterine cancer	2.74e-05	0.00182	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—FGFR2—uterine cancer	2.72e-05	0.0018	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP11A1—uterine cancer	2.61e-05	0.00173	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STK11—uterine cancer	2.5e-05	0.00165	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CCL2—uterine cancer	2.48e-05	0.00165	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.48e-05	0.00164	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKR1C3—uterine cancer	2.47e-05	0.00164	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.44e-05	0.00162	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.4e-05	0.00159	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SOCS3—uterine cancer	2.34e-05	0.00155	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ESR1—uterine cancer	2.33e-05	0.00154	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN2B—uterine cancer	2.24e-05	0.00148	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—NRAS—uterine cancer	2.2e-05	0.00146	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1R—uterine cancer	2.17e-05	0.00144	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL8—uterine cancer	2.16e-05	0.00143	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCL2—uterine cancer	2.05e-05	0.00136	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SMAD3—uterine cancer	2.04e-05	0.00135	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NDUFB11—uterine cancer	2.02e-05	0.00134	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SRD5A2—uterine cancer	2.02e-05	0.00134	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL8—uterine cancer	1.96e-05	0.0013	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.96e-05	0.0013	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGFR2—uterine cancer	1.95e-05	0.00129	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP19A1—uterine cancer	1.92e-05	0.00128	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—STK11—uterine cancer	1.92e-05	0.00128	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—uterine cancer	1.92e-05	0.00127	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KRAS—uterine cancer	1.89e-05	0.00126	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.85e-05	0.00123	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.81e-05	0.0012	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—uterine cancer	1.74e-05	0.00115	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.72e-05	0.00114	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB2—uterine cancer	1.71e-05	0.00113	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ESR1—uterine cancer	1.67e-05	0.00111	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL8—uterine cancer	1.62e-05	0.00107	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—uterine cancer	1.61e-05	0.00107	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1B—uterine cancer	1.58e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NRAS—uterine cancer	1.58e-05	0.00104	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—uterine cancer	1.57e-05	0.00104	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNB1—uterine cancer	1.5e-05	0.000992	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCL2—uterine cancer	1.47e-05	0.000973	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.46e-05	0.000967	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—STAR—uterine cancer	1.46e-05	0.000967	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—uterine cancer	1.46e-05	0.000966	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MTHFR—uterine cancer	1.45e-05	0.000958	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.44e-05	0.000956	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—uterine cancer	1.42e-05	0.000943	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EP300—uterine cancer	1.39e-05	0.000922	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—uterine cancer	1.37e-05	0.00091	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—uterine cancer	1.36e-05	0.000899	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.33e-05	0.000882	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.33e-05	0.000882	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—uterine cancer	1.32e-05	0.000873	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRAS—uterine cancer	1.3e-05	0.000862	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.27e-05	0.000844	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—uterine cancer	1.25e-05	0.000826	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—uterine cancer	1.22e-05	0.000811	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL8—uterine cancer	1.16e-05	0.000769	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—uterine cancer	1.15e-05	0.000764	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—POLD1—uterine cancer	1.14e-05	0.000759	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1B—uterine cancer	1.13e-05	0.000751	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—uterine cancer	1.12e-05	0.000743	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—uterine cancer	1.12e-05	0.000742	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.07e-05	0.00071	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNB1—uterine cancer	1.07e-05	0.00071	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—uterine cancer	1.04e-05	0.000692	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—uterine cancer	1.03e-05	0.000682	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—uterine cancer	1.02e-05	0.000675	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EP300—uterine cancer	9.95e-06	0.00066	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—uterine cancer	9.95e-06	0.00066	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—STAR—uterine cancer	9.62e-06	0.000638	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.62e-06	0.000638	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—RRM2—uterine cancer	9.54e-06	0.000633	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—uterine cancer	9.51e-06	0.000631	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—uterine cancer	9.42e-06	0.000625	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRAS—uterine cancer	9.31e-06	0.000617	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DCN—uterine cancer	9.26e-06	0.000614	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP11A1—uterine cancer	8.73e-06	0.000579	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—uterine cancer	8.4e-06	0.000557	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKR1C3—uterine cancer	8.24e-06	0.000546	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—uterine cancer	8.04e-06	0.000533	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—uterine cancer	8.01e-06	0.000531	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—EP300—uterine cancer	7.67e-06	0.000508	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—POLD1—uterine cancer	7.55e-06	0.0005	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—uterine cancer	7.36e-06	0.000488	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—uterine cancer	7.12e-06	0.000472	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.06e-06	0.000468	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—uterine cancer	6.81e-06	0.000451	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—STK11—uterine cancer	6.42e-06	0.000426	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP19A1—uterine cancer	6.42e-06	0.000426	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RRM2—uterine cancer	6.29e-06	0.000417	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DCN—uterine cancer	6.11e-06	0.000405	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.03e-06	0.0004	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—uterine cancer	6.01e-06	0.000399	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.76e-06	0.000382	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.75e-06	0.000381	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—uterine cancer	5.67e-06	0.000376	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.44e-06	0.00036	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTHFR—uterine cancer	4.82e-06	0.00032	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—uterine cancer	4.63e-06	0.000307	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.25e-06	0.000282	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.23e-06	0.000281	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—STK11—uterine cancer	4.23e-06	0.000281	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTHFR—uterine cancer	3.18e-06	0.000211	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—uterine cancer	2.68e-06	0.000178	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—EP300—uterine cancer	2.56e-06	0.00017	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.89e-06	0.000126	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—uterine cancer	1.77e-06	0.000117	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—EP300—uterine cancer	1.69e-06	0.000112	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—uterine cancer	1.55e-06	0.000103	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.25e-06	8.28e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—uterine cancer	1.02e-06	6.76e-05	CbGpPWpGaD
